With today’s announcement, Tilray products are now available in eight countries spanning four continents.
To distribute its products nationwide, Tilray has partnered with pharmaceutical wholesaler NOWEDA and service provider Paesel + Lorei.
Tilray medical cannabis products have been successfully exported to New Zealand and are now available for distribution nationwide
Tilray will invest €20 million in a European Union Campus to cultivate, process, package, and distribute medical cannabis to patients, pharmacies, and researchers throughout the Europe.
Tilray's two facilities will generate a combined production capacity of up to 51 metric tonnes per year, which will position Tilray to respond to significant projected growth in demand for its medical cannabis products.
Tilray partners with the Research Institute of the McGill University Health Centre to study the efficacy of medical cannabis in patients with chronic obstructive pulmonary disease (COPD).
Tilray products have arrived and are cleared for distribution in Cyprus, a European Union member state. In 2016, Tilray became the first company to export medical cannabis products from North America to the European Union.
“We are proud to be able to offer Australian patients in need access to high quality, pharmaceutical-grade medical cannabis products in accordance with quality standards mandated by the Australian government,” said Brendan Kennedy, Tilray President.
According to the government of Victoria, 29 critically ill children will become the first patients in the Australian state to legally access medical cannabis when the Tilray products are distributed.
Tilray will supply Middlemore Hospital in Auckland with precisely formulated medical cannabis oil containing tetrahydrocannabinol (THC) and cannabidiol (CBD).
Tilray, a global leader in medical cannabis research and production, today announced that it has received necessary regulatory approvals in Canada and Chile to export medical cannabis for distribution to Chilean patients.
As North America’s only GMP certified medical cannabis producer, Tilray is uniquely positioned to expand distribution of its pharmaceutical-grade medical cannabis products.
This trial is a critical step to uncovering an effective way to alleviate the seizure burden in this population of children with a rare, difficult-to-treat disease.
The trial will be one of the world’s first large-scale clinical trials to examine medical cannabis as a treatment for a mental health disorder.
Discovering that CBD was an undeveloped potential anticonvulsant that might help thousands of children changed the course of my career. I’m now the clinical research director for Tilray, a medical cannabis company that provides patients with access to safe, reliable and consistent products to treat a wide variety of ailments.
THE GLOBE AND MAIL
Despite a Supreme Court of Canada decision that gives sick Canadians the right to use medical cannabis oils, Ottawa is reimbursing the country’s veterans for dried pot only, potentially pushing them to less healthy options of smoking or vaporizing the drug. Mr. Lucas, also head of patient services at Nanaimo-based grower Tilray, recently launched an e-petition sponsored by his local MP, New Democrat Sheila Malcolmson, asking Veterans Affairs to begin covering these extracts.
Neuroscientist Catherine Jacobson told her story to the cannabis medical conference at Harvard. She now heads clinical research for Tilray, a Canadian medical marijuana company trying to turn cannabis into conventional medicine.
BUSINESS NEWS NETWORK
Tilray, a Canadian cannabis producer, recently announced that it received approval to ship two varieties of liquid capsules to Croatia. Brendan Kennedy, Global President with Tilray says that Europe presents a good growth opportunity for Tilray.